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Abstract 
Fever associated with neutropenia, blood transfusion and disease processes is common 
in adult cancer patients. The literature indicates however that the aetiology, rationale and 
symptoms of fever are often misunderstood, resulting in fever management that is not 
evidence-based in this cohort. Thus in this review, an overview of fever, with a focus on 
fever in cancer contexts, is provided. Content includes an explanation of the therapeutic 
function of fever, an analysis of the physiological consequences of fever and an 
exploration of the aetiology of fever in cancer patients. Current guidelines for fever 
management in cancer patients and existing nursing practice are also discussed. 
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Background 
Fever associated with neutropenia, blood transfusion and disease processes is 
common in adult cancer patients. The literature indicates however that the aetiology, 
rationale and symptoms of fever are often misunderstood, resulting in fever 
management that is not evidence-based in this cohort. In an attempt to understand 
these issues, this paper reviews these issues to establish the current state of the 
evidence.  
Using specific search terms to address five topics (‘fever generation’, ‘effects of fever’, 
‘aetiology of fever’, ‘nursing fever assessment’, ‘nursing fever management’), the 
CINAHL, PubMed, JBI and Cochrane databases, were searched. Findings were 
restricted with language (‘English’) and year of publication (‘between 2005 to 2014’).  
 
Fever generation 
Pathogens tend to function most effectively in a defined range of normal body 
temperature. Fever occurs as a therapeutic response to the presence of pathogens and 
is considered to be therapeutic fever1. It is the body’s defensive mechanism, increasing 
the hypothalamic set-point beyond the level compatible with pathogenic function2. Body 
temperature regulation is a homeostatic mechanism. When the core body temperature 
exceeds the limit of the normal range of internal body temperature, called the set-point, 
heat loss mechanisms are activated. These include vasodilation and sweating. Heat 
production mechanisms, such as vasoconstriction and shivering, are stimulated when 
the core body temperature falls below the set-point3.  
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Multiple systems including the immune, nervous, and cardiovascular systems are 
involved in fever generation, which comprises three distinct phases. In the chill phase, 
which is the initial phase of fever, the immune system responds to infection and 
inflammation by releasing pyrogenic cytokines such as interleukin-1 and interleukin-64. 
These cytokines stimulate the activation of the arachidonic acid cascade. Prostaglandin 
E2 (PGE2) is then released from the cells of the immune system as part of the 
arachidonic acid cascade4. PGE2 affects thermoregulation in the central nervous 
system, resulting in a recalibration of the temperature set-point to a higher level than 
normal1. Patients react to an increase in the set-point with chilling and vasoconstriction 
to decrease heat loss and increase heat production3. The central nervous system sends 
out signals in response to the elevated set-point via the motor and sympathetic nervous 
systems, initiating shivering. Shivering, which generates heat, is controlled by the motor 
system, while constriction of the skin’s blood flow to restrict heat loss is mediated by the 
alpha-1 adrenergic receptors of the sympathetic nervous system5. The next phase of 
fever is the plateau phase. In this phase, the core temperature reaches the new set-
point and shivering stops due to the balance between heat production and heat loss. 
This second phase is followed by the defervescence phase, when the pathogenic 
agents are neutralised6. In this last phase, the endogenous pyrogen levels fall, resulting 
in the reduction of the set-point to a lower or normal level. Patients react with sweating 
and vasodilation to release the excess heat generated in the previous phase3. 
 
Benefits of fever 
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The balance between fever risks and benefits has been the subject of much controversy 
in recent years. Fever is a normal body defence in response to a perceived threat to the 
immune system that marshals innate, adaptive and neuro-endocrine responses. 
Homeostatically, an elevated temperature enhances immune system function7. 
Elevations in body temperature can improve the efficiency of macrophages in killing 
invading bacteria, and limit the available iron needed for the replication of many 
microorganisms8. Fever also enhances immunologic functions such as the lymphocyte 
response to mitogens, the bactericidal activity of neutrophils, the production of interferon, 
and the secretion of corticotrophin and cortisol5. A number of intervention studies support 
the notion that fever is an important physiological response to infection and that the 
administration of regular paracetamol to reduce fever is associated with a reduced 
antibody response, delayed recovery and the prolongation of symptoms8,9.  
 
Side-effects 
Despite its therapeutic intent, fever also has adverse side effects such as dehydration 
and an increased metabolic rate. It is reported that a 1°C increase in temperature over 
37°C results in a 10%-12% increase in metabolic rate and the loss of 250ml of fluid from 
the body in 24 hours10. Shivering in fever can increase the metabolic rate from 100% to 
200%, leading to increased oxygen consumption and carbon dioxide production10. 
Patients who have respiratory, cardiovascular or metabolic disorders find it difficult to 
tolerate the increased rate of oxygen consumption caused by fever3. Fever in these 
patients should be reduced to prevent deterioration.  
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Overall, fever enhances the body’s immune system, which strengthens the normal body 
defence. Nevertheless, the physiological response to fever might be harmful for patients 
in some cases. For example, in cancer, fever can be a sign of drug allergy to the 
monoclonal antibodies often used in cancer therapy11, 12. In addition, febrile neutropenia 
is one of the major causes of chemotherapy interruptions and dose reductions, which can 
potentially compromise the efficacy of cancer treatment, add considerably to the length 
and cost of treatment and adversely affect survival outcomes in curative settings13, 14. It is 
therefore important to be able to differentiate between the causes and effects of fever to 
determine the most appropriate response.  
 
Aetiology of fever in cancer patients 
Infectious origin 
Studies indicate that the infectious origins of fever in cancer patients are bacterial, fungal 
and viral15, 16, 17. A prospective study (2000-2001) audited the cause of fever among 371 
hospitalised neutropenic and non-neutropenic cancer patients. Amongst 477 febrile 
episodes, infection was reported as the main cause (67%, n=319)15. Amongst 206 
infectious episodes where the pathogen was identified, bacteria were the most frequent 
cause (90%, n=256), followed by fungi (6%, n=17) and viruses (4%, n=11). Gram-
negative bacilli predominated (48%, n=137) in comparison with Gram-positive cocci 
(33.5%, n=95) and Gram-positive bacilli (4.6%, n=13). The most frequent site involving 
infection was the respiratory tract (29%, n=92), followed by secondary bacteraemia 
(16%, n=50) and the urinary tract (12.9%, n=41). According to Toussaint and colleagues, 
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fever of infectious origin in neutropenic patients (n=239 in 357 episodes) was not 
significantly more frequent than in non-neutropenic patients (n=80 in 115 episodes, 
p>0.05)15. 
 
These findings are supported by further studies. For example, a retrospective audit 
(2001-2006) of 95 acute myeloid leukaemia patients during chemotherapy (382 febrile 
episodes) reported a similar incidence of infectious aetiology (64%, n=244)16. 
Respiratory tract infections were the most common (27%, n=46) in 170 episodes that 
could determine sites of infection. Bacteria were the most common origin of infection 
(88%, n=72) of 82 episodes in which microbiological isolates could be obtained, followed 
by fungi (n=60 episodes). Gram-negative organisms predominated (63%, n=60)16. 
Another retrospective study (2007-2008), which collected data from a computerized 
registry of 3,197 cancer patients (869 febrile episodes), confirmed similar findings17. In 
Pagano et al’s study, infection was the most common cause of fever (50%, n=435) of 
which 301 episodes were initiated by bacterial infection, followed by fungi (13.9%, 
n=121) and viruses (1.8%, n=16)17. Eighty-five percent (241 cases) occurred in the blood 
stream (216 cases were primary sepsis), followed by the respiratory tract (10.6%, 
n=30)17.  
 
Chemotherapy is one of the most common indirect instigators of fever in cancer patients, 
as it causes bone marrow suppression. White blood cells (WBCs) usually reach their 
lowest levels seven to 14 days after chemotherapy and take one to two weeks to recover 
spontaneously, leading to the risk of infection18. The incidence of febrile neutropenia in 
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patients receiving chemotherapy varies from 6% in patients having breast cancer, to an 
estimated 10–50% of patients with solid tumours and in more than 80% of patients with 
haematological malignancies19. The frequency of infections ranges from 35% to 78% 
during induction chemotherapy, and up to 65% during consolidation chemotherapy in 
acute leukaemia patients16. When chemotherapy is used to decrease tumour size prior to 
surgery, surgery can only be performed when there is adequate bone marrow recovery 
after chemotherapy. However, post-chemotherapy tumour resections tend to be lengthy 
surgical procedures, increasing the risk of infection that then further raises fever 
incidence20. Oncology patients might be at high risk of postoperative fever due to low 
baseline health status, could be malnourished and have chronic immunosuppression 
from multiple cycles of chemotherapy20.  
 
Non-infectious origin 
Cancer is associated with non-infectious fever due to the allergic and inflammatory 
responses that result from tumour necrosis and the thrombotic events that result from 
cancer-related conditions such as disseminated intravascular coagulation21. All of these 
processes are associated with the production of pyrogenic cytokines. Tumours can also 
increase susceptibility to infection through the destruction of normal anatomical 
barriers19. For example, Toussaint cites 112 cases of non-infectious fever in cancer 
patients, attributed to the tumour itself (27%, n=42), followed by medication (18%, n=28) 
and post-surgical procedures (17%, n=26)15.  
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Blood transfusion in cancer patients is also associated with the risk of fever22. 
Transfusions of blood products provide vital haemodynamic and other support for 
oncology patients. They are indispensable in the treatment of patients with cancer, 
particularly those with leukaemia, lymphoma, and those requiring stem cell transplant. 
However, blood transfusions carry risks of adverse reactions to blood components and of 
infection owing to undetected viruses and/or bacteria in the blood products22. This can 
lead to febrile haemolytic, febrile non-haemolytic and bacterial febrile reactions. In 
haemolytic reactions, immediate onset of fever can occur during or after the 
administration of blood due to antigen incompatibility, followed by other severe reactions 
events such as chest pain, shock and renal failure21. Febrile non-haemolytic transfusion 
reactions, the most commonly reported transfusion reaction, have a complex aetiology22. 
These reactions are primarily due to anti-leukocyte antibodies in the recipient, which 
react to the antigens of transfused white blood cells. Febrile non-haemolytic transfusion 
reaction is characterized by chills, fever with a rise of temperature of at least 10C within 
four hours of transfusion (usually within a few minutes), and defervescence within 48 
hours1. In addition, febrile reactions can result from bacterial antigens or endotoxins in 
the carrying solution or the tubing. Bacterial contamination can also be transmitted from 
a donor or during collection, processing, or storage of blood products. In these instances, 
fever can occur immediately after the infusion has started1. 
 
In addition, fever can be a possible adverse event in patients receiving monoclonal 
antibodies21, 23. Monoclonal antibodies are artificial immune system proteins that are 
able to bind the specific membrane surface proteins of a cancer cell to inhibit their 
9 
 
replication23.  Some cancer cells contain membrane surface proteins that are unique to 
cancer cells. Monoclonal antibodies recognise those proteins as foreign antigens and 
attach to them, thereby preventing cell division24. However, during this process 
monoclonal antibodies can cause allergic reactions, including fever11, which in some 
instances can be life- threatening24.  
 
Fever of unknown origin 
Fever of unknown is defined as recurrent fever of 38.30C or higher of at least 3 weeks, 
where no certain diagnosis of the fever cause can be identified after one week of 
investigation in hospital25. Febrile episodes associated with tumours have been reported 
because tumours can cause prolonged fever by intermittent necrosis with subsequent 
phagocytosis and cytokine production26. One large population-based study (n=43,205) 
showed that fever of unknown origin in cancer patients is associated with haematologic 
malignancies and some solid tumours25.  
 
Despite different methodologies and samples, these studies provide evidence that 
cancer patients are clearly vulnerable to numerous sources of fever. Whilst fever is 
beneficial for the body in many ways, there is a need to manage it effectively in 
oncology patients to avoid unwanted consequences. Current guidelines for fever 
assessment and management in cancer patients are now reviewed. 
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Current guidelines for fever management in cancer patients 
Nursing fever assessment 
Non-invasive methods of measuring body temperature in the mouth, tympanic 
membrane, temporal artery and axillae are often used in practice27. However, there is 
conflicting evidence concerning the accuracy, precision, reliability and practicality of each 
type of non-invasive temperature measurement method28,29,30,31. Oral temperature is 
recommended by the Clinical Practice Guideline of Infectious Disease Society of 
America (IDSA) to define febrile episodes in neutropenic patients with cancer32. 
According to IDSA, axillary temperature does not provide an accurate core body 
temperature and rectal temperature should be avoided for hygiene reasons32. However, 
the guideline does not recommend alternatives for patients whose temperature cannot 
be measured by mouth, such as those with oral cancer. In addition, a study by Ciuraru 
and colleagues revealed that mucositis, an inflammatory process common in cancer 
patients, might result in an apparently increased oral temperature when compared with 
tympanic temperature readings, leading to misdiagnosis of fever33. This conclusion 
should be viewed with caution, however, as the study was limited by a small sample size 
(n=25 patients having mucositis) and used tympanic temperature as the reference 
standard, which itself is unreliable33. Their use of tympanic temperature was supported 
by Dzarr’s prospective study, which reported that tympanic temperature readings were 
more consistent with rectal than oral and axillary temperature readings34. Although 
similarly small in sample, 21 haematology patients were recruited through convenience 
sampling in this study to simultaneously record oral, rectal, axillary and tympanic 
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temperature readings twice a day until neutrophil counts recovered34. Amongst 400 
separate temperature readings, tympanic thermometry had the highest agreement with 
rectal thermometry (intraclass correlation coefficient, ICC = 0.8), compared to the 
agreement between oral, axillary and rectal measures (ICC = 0.486)34. In contrast, 
several studies used oral temperature as the reference standard to evaluate the 
accuracy of tympanic temperature and concluded that tympanic temperature should not 
be used as it tends to yield inaccurate readings28,35,36. 
 
Nursing fever management 
Pharmacological and non-pharmacological interventions, alone or in combination, are 
the mainstay of nursing fever management. Non-pharmacological interventions, mainly 
based on external cooling methods, are believed to promote heat loss through the skin 
by conduction, convection or evaporation37. While the set-point hypothalamic 
temperature remains, these cooling methods actually raise core heat production in 
response to peripheral cooling. Thus, external cooling methods potentially lead to 
several adverse effects such as increased metabolic rate, increased oxygen 
consumption, shivering, vasoconstriction, vasospasm of coronary arteries and rebound 
hypothermia37. Therefore, external cooling should not be used until after antipyretic 
drugs have started to lower the elevated set-point, and only for comfort reasons38,39.  
 
Drugs are used to both treat symptoms and to address the underlying cause of the 
fever. Antipyretic drugs used for symptom management, such as paracetamol, are 
believed to inhibit cyclo-oxygenase40. This enzyme is responsible for the release of 
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prostaglandins from arachidonic acid, so its inhibition results in a lowering of the set-
point temperature in the hypothalamus. Heat loss mechanisms are activated and thus 
body temperature is reduced1,37. Considerable risks of adverse effects of antipyretics, 
such as hypotension, liver damage, interactions with other drugs, renal and hepatic 
toxicity have been confirmed in children treated for cancer and in patients who use 
paracetamol chronically1,37. Furthermore, although the results of some comparative 
studies and reviews are inconsistent and inconclusive, none of them found that 
antipyretics reduced the duration of the illness causing the fever41. Indeed, evidence 
suggests that antipyretics can prolong the illness in patients with fever41. The risks and 
benefits of pharmacological and non-pharmacological methods to reduce fever are 
many and as such, their use should be carefully considered in cancer patients and 
tailored to their therapeutic situation37,39,41. 
 
Of more use are antimicrobial drugs, such as antibiotics, anti-virals and anti-fungals, 
which are used to both pre-empt and to treat the underlying cause of fever. Infection in 
neutropenic cancer patients is associated with significant morbidity and mortality, so it is 
common practice to treat all febrile neutropenic patients with broad spectrum 
intravenous antimicrobials whether the cause of the fever is known or not20. Prophylaxis 
with granulocyte colony stimulating factor (G-CSF) is also routine in febrile neutropenic 
patients to enhance their ability to mount a therapeutic defence by hastening white 
blood cell production32. In recent years, standardised tools and a number of guidelines 
have been developed for systematic assessment of febrile neutropenic risk in individual 
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patients42. These guidelines, which are widely accepted, clarify whether fever in cancer 
patients should be treated and how it should be treated.  
 
A number of evidence-based guidelines for fever management in adult cancer patients 
exist, which indicates the general awareness of the vulnerability of cancer patients 
during febrile episodes and the need to manage fever appropriately in those 
patients32,43,44,45. However, those guidelines do not embrace some relevant issues. First, 
cancer-focused guidelines for fever management mainly approach febrile episodes in 
neutropenic patients while other types of cancer patients, for example those 
experiencing fever as a result of their disease process or as an adverse event of 
immunological therapies, are not mentioned32,44. Secondly, although guidelines 
emphasise pharmacological therapy such as antibiotics, antimicrobials or prophylaxis 
with granulocyte colony stimulating factor (G-CSF), the appropriate use of antipyretics 
(such as paracetamol) is not discussed at all, and neither is the key role of nurses in 
fever management32,45. Moreover, although in some policies fever is defined an oral 
temperature of 38°C and above, few if any guidelines recommend the optimal way to 
measure it, the alternative site if an oral reading cannot be obtained, nor the optimal 
measurement methods to ensure accuracy and consistency across measures on the 
one patient and measures between patients32.  
 
This confusion is mirrored in nursing practice. Research consistently suggests that 
nurses often do not fully understand the aetiology, rationale and symptoms of fever and 
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do not practise evidence-based fever management46,47. Recent studies report that 
between 30% and 50% of nurses invariably regard fever as a harmful event requiring 
aggressive treatment46. Different studies report that nurses tended to treat fever and 
consider management options based on the temperature value alone rather than 
consideration of symptoms48,49,50,51. This is despite the fact that the threshold reported 
by nurses varied from 37.50C to 410C50. In addition, they also reported different choices 
of interventions, even those that are contraindicated such as ‘alcohol’ and ‘ice packs to 
the groin’48,51. When asked for the rationale underpinning their choice of interventions, 
some responded that they based their decisions on ‘what worked’ in the past for other 
nurses or their own experiences48.  
 
These studies have many limitations however, including small sample sizes and lack of 
validated tools, therefore it is difficult to draw definitive conclusions from them. There is 
only one oncology-specific study, undertaken in 2013, which surveyed an online 
convenience sample of 54 nurses and doctors in cancer care52. Its findings are similarly 
difficult to generalise to oncology nursing due to a number of limitations. For example, 
the sample size is small, the validity and reliability of the instrument used to measure 
nurses’ knowledge and attitudes is not reported, there is potential for participation bias 
as the survey was available only with online access, and the aggregate reporting of 
results means the responses of the nurses and physicians cannot be determined.  
 
Conclusion 
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 While fever is a natural and often therapeutic response in cancer patients, an 
understanding of its nature and potential effect on the patient should guide subsequent 
nursing management. Unfortunately, research indicates that there are many 
inconsistencies in the assessment and management of fever in cancer patients, and 
extant practice guidelines do not provide comprehensive or even evidence-based 
information as to appropriate nursing responses and the reduction of risk to patients. It 
is timely then to consider research to generate the high level evidence required to guide 
cancer nursing assessment and management.  
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